Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Information Today January 14, 2013 George H. Pike	Google Reaches Settlements With FTC Over Search, Patent Practices On Jan. 3, 2013, the U.S. Federal Trade Commission and Google reached a series of agreements that closed the FTC's investigation into several of Google's business practices, in return for Google's agreement to modify those practices.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
Prepared Foods May 4, 2007 Mark Hostetler	Claims Substantiation for Weight Management Products There is regulatory guidance available to help answer the question of how much and what kind of claims support is required.
Chemistry World November 24, 2015 Phillip Broadwith	Toeing the advertising line When it comes to advertising pharmaceuticals, companies have to tread a little more carefully.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
Inc. March 2004 Lora Kolodny	Bad Patent Reform Pending patent reform could leave entrepreneurs unprotected.
InternetNews January 5, 2006 Roy Mark	Bogus Spyware Vendors Settle FTC Charges The Federal Trade Commission slaps almost $2 million in fines on firms selling software that did not remove spyware as advertised.
The Motley Fool July 9, 2010 Brian Orelli	Changing Pay-For-Delay Will Hurt Everyone Whether you're an investor in brand-name drugs or in companies that make generics, FTC chairman Jon Leibowitz is not your friend.
Entrepreneur May 2004 Jane Easter Bahls	The Jig Is Up Be careful not to mislead your customers with your advertising--or you might risk a nasty run-in with the FTC and the Lanham Act.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
Bio-IT World November 19, 2004 Lentini & Bent	Intellectual Property: Patents and Genomic Medicine Patents, so critical to encouraging investment in developing new technologies, threaten to become a legal and economic minefield that could prevent effective commercial exploitation of genomics.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
Chemistry World April 2, 2007	European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.
Chemistry World June 1, 2015 Phillip Broadwith	Teva fined $1.2bn in pay-for-delay case Israeli firm Teva has reached a settlement with the US Federal Trade Commission over allegations of cutting illegal deals with generic drugmakers to stifle competition for sleep disorder drug Provigil (modafinil).
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
Science News August 10, 2002 Janet Raloff	Diet Pills: It's Still Buyer Beware On the dangers and uncertainties associated with non-prescription diet pills
Bio-IT World June 17, 2004 Hope Melville	Is It Safe? Think the safe harbor provision in patent law lets you use patented compounds in all preclinical-phase research? Think again.
InternetNews April 1, 2005 Roy Mark	Diet Patch Spammers Settle With FTC Court rejects their claim that only affiliate marketers should be held responsible.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
IEEE Spectrum June 2007 Suhas Sreedhar	Peer Review Starts for Software Patent Applications Hoping to curtail the orgy of tech-industry litigation, the U.S. Patent and Trademark Office recently launched an Internet-based peer-review program whereby anyone can help to evaluate a number of software patent applications voluntarily submitted for public evaluation.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
Food Processing January 2013 Thomas Hanrahan	Food Becomes Target for Consumer Lawsuits Lawyers who made their fortunes suing tobacco companies have set their sights on the food industry.
CFO Kris Frieswick	Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist...
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
Prepared Foods October 1, 2006 Steven B. Steinborn	An Apple a Day...but How Big an Apple? When deciding how much of an ingredient or nutrient must be added to a product to justify its advertising claim, certain regulatory guideposts should be followed.
The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
Pharmaceutical Executive August 1, 2005 Jill Wechsler	Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.
InternetNews October 20, 2006 Roy Mark	'Net Vendors of Diabetes Cures on Notice The Federal Trade Commission and the Food and Drug Administration are teaming with Mexico and Canada to stop deceptive advertising and product sales of purported diabetes cures and treatments.
InternetNews February 2, 2004 Zachary Rodgers	Rich Media Ad Players Irked, Despite Reprieve Microsoft holds off on releasing the new versions of IE and Windows that would pose problems for rich media. So why are publishers and ad serving firms peeved?
Bio-IT World November 12, 2002 Beth E. Arnold	Navigating Gene Patent Minefields As the number of gene-related patents soars, so do the chances of patent infringement. Here are tips to avoid a costly misstep in this legal minefield.
Chemistry World August 23, 2012 Dean Baker	Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue.
Pharmaceutical Executive May 1, 2005 Margaret Buck	Legal: No Exception? An important legal loophole has made patented tools available for biotech research. Today, though, it appears to be closing.
InternetNews April 16, 2004 Susan Kuchinskas	No Obvious Solutions for IT Patent Reform Lack of time and funds plus unclear standards plague the process, said attendees of a UC Berkeley conference.
Information Today September 15, 2011 George H. Pike	Congress Enacts Patent Reform Legislation In what is being described as the most substantial overhaul of U.S. patent law in nearly 60 years, Congress passed the Leahy-Smith America Invents Act, patent reform legislation that has been years in the making.
InternetNews August 16, 2005 Roy Mark	Site Settles Deceptive Credit Report Claims FTC imposes a $950,000 fine and requires consumer restitution from Consumerinfo.com, which misled consumers with promises of a free credit report.
Information Today October 16, 2006 K. Matthew Dames	The Patent System on Tilt: IBM Seeks to Change the Game IBM wants to change the way the patent system works, holding itself out as an exemplar of openness.
Inc. July 24, 2002 Jennifer A. Redmond	Strategic Patenting What to consider when you're filing a patent and strategic decisions you'll need to make.
InternetNews August 10, 2004 Roy Mark	FTC Settles with Pop-up Ad Operators Scheme involved exploiting Windows Messenger Service to barrage consumers with ads.
CRM November 26, 2012 Judith Aquino	Social Media Ad Revenue to Reach $9.2 Billion by 2016 Ads on social networks are going native, reports BIA/Kelsey.
Chemistry World November 2, 2007 Rebecca Trager	GSK Blocks US Patent Law Changes Pharmaceutical giant GlaxoSmithKline (GSK) has temporarily blocked the US Patent and Trademark Office from implementing new rules, which it fears could prevent innovators from obtaining adequate patent coverage on their inventions.
InternetNews July 28, 2004 Susan Kuchinskas	Google's Ad Technology Tussle Marching headlong into the public arena, Google is wrangling over ad technology -- and words -- in a patent suit with Overture.
Information Today July 2, 2013 George H. Pike	Why Patent Litigation Was on the Upswing in 2012 2012 was a "banner year in patent litigation," with increases in the number of patent infringement lawsuits filed in the federal courts and larger damage awards.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
InternetNews March 16, 2004 Susan Kuchinskas	Patently Unfair? Overworked patent examiners and outdated rules are just two of the reasons critics of some tech patents say the process needs fixing.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
InternetNews March 10, 2005 Susan Kuchinskas	Mr. Smith Went to Washington For Patent Reform Microsoft General Counsel Brad Smith calls for patent reform at the American Enterprise Institute.